Starling Oncology, Inc. (STLN) P/E Ratio History
Deep ValueTrading at -100.3x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2022–2022
Loading P/E history...
P/E Ratio Analysis
As of November 18, 2026, Starling Oncology, Inc. (STLN) trades at a price-to-earnings ratio of -100.3x, with a stock price of $3.40 and trailing twelve-month earnings per share of $-0.03.
The current P/E is 198% below its 5-year average of 101.9x. Over the past five years, STLN's P/E has ranged from a low of 101.9x to a high of 101.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.9x, STLN trades at a 503% discount to its sector peers. The sector includes 251 companies with P/E ratios ranging from 0.0x to 184.2x.
Relative to the broader market, STLN trades at a notable discount to the S&P 500 median P/E of 21.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our STLN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
STLN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
STLN P/E vs Peers
Outpatient & Specialty Clinics peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 22.1 | - | +3% | |
| $2B | 20.3 | 1.01 | +23% | |
| $364M | 9.0Lowest | - | -15% | |
| $127B | 27.1 | - | +49%Best | |
| $65B | 35.8 | 1.26 | +12% | |
| $47B | 46.9 | 2.58 | +26% | |
| $6B | 41.8 | 0.80Best | -12% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
STLN Historical P/E Data (2022–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q1 | - | $7.13 | $0.07 | 101.9x | +0% |
Average P/E for displayed period: 101.9x
STLN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
STLN — Frequently Asked Questions
Quick answers to the most common questions about buying STLN stock.
What is STLN's P/E ratio?
Starling Oncology, Inc. (STLN) trailing twelve-month P/E ratio is -100.3x, based on TTM diluted EPS of $-0.03. The 5-year average P/E is 101.9x and the historical range spans 101.9x to 101.9x.
Is STLN stock overvalued or undervalued?
STLN trades at -100.3x P/E, below its 5-year average of 101.9x. At the 0th percentile of its historical range (101.9x–101.9x), the stock is priced at a discount to its own history.
Is STLN stock expensive?
No, STLN is not expensive on a historical basis. The current P/E of -100.3x is below the 5-year average of 101.9x and sits at the 0th percentile of its valuation range.
What is STLN's historical P/E range?
Over the past 5 years, STLN's P/E ratio has ranged from 101.9x to 101.9x, with a median of 101.9x and an average of 101.9x. The current P/E of -100.3x places the stock at the 0th percentile of this range. Full historical data spans 2022–2022.
How does STLN's P/E compare to the S&P 500?
STLN trades at -100.3x P/E versus the S&P 500 median of 21.5x. The 567% discount to the market suggests lower growth expectations or perceived higher risk.
How does STLN's valuation compare to Healthcare peers?
Starling Oncology, Inc. P/E of -100.3x compares to the Healthcare sector median of 24.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is STLN's PEG ratio?
STLN PEG ratio is N/A. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is STLN's earnings yield?
STLN earnings yield is N/A, the inverse of its -100.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.